¿3-Dimensional Pharmaceuticals Inc., of Exton, Pa., said underwriters for its recent initial public offering purchased another 750,000 shares at $15 each pursuant to their overallotment option. That increased the IPO to 5.75 million shares and gross proceeds to $86.25 million. 3DP's DiscoverWorks technologies are designed to accelerate and improve the drug discovery process. (See BioWorld Today, Aug. 7, 2000, p. 1.)
¿Affymetrix Inc., of Santa Clara, Calif., entered into a BiotechAccess agreement with deCode Genetics Inc., of Reykjavic, Iceland, under which deCode well gain broad access to Affymetrix's GeneChip arrays, instrumentation and software to monitor gene expression.
¿Amylyn Pharmaceuticals Inc., of San Diego, said a Phase II dose frequency study of AC2993 (synthetic exendin-4) in Type II diabetics showed the product lowered blood glucose. Each of three injection frequencies resulted in lower 24-hour mean plasma glucose concentrations compared to placebo. Additional data will be presented at the ADA meeting in San Antonio, Texas, on June 12.
¿Anadys Pharmaceuticals Inc., of San Diego, granted Pharmacia Corp. a non-exclusive license to its Genetics Assisted Target Evaluation technology for use in the discovery and validation of novel targets for antifungal drugs. Anadys will receive licensing fees and research payments.
¿Arena Pharmaceuticals Inc., of San Diego, said underwriters of its recent initial public offering exercised their overallotment option on an additional 900,000 shares at $18 per share. The IPO total is 6.9 million shares, for gross proceeds of $124.2 million. The company uses its CART technology to identify new drug candidates. (See BioWorId Today, JuIy 31, 2000, p. l.)
¿Argonaut Technologies Inc., of San Carlos, Calif., said underwriters of its recent initial public offering exercised their overallotment option on an additional 690,000 shares. The IPO now entails 5.26 million shares at $15 per share, bringing total proceeds before expenses to $73.8 million. The company's products help chemists use highspeed parallel synthesis for the development of new drugs. (See BioWorld Today, May 1, 2000, p. 1: and July 31, 2000, p. 1)
¿Aventis Behring LLC, of King of Prussia, Pa., said the European Commission approved Helixate NexGen, a recombinant product for the treatment of hemophilia A.
¿Genometrix Inc., of The Woodlands, Texas, and Genomics Collaborative Inc., of Cambridge, Mass., are collaborating to analyze thousands of clinically characterized DNA samples for profiling single nucleotide polymorphisms. The study is focused on hypertension.
¿GenVec Inc., of Gaithersburg, Md., said it began Phase II studies of BioBypass angiogenic agent in patients with peripheral vascular disease. It is the company's lead product and is designed to improve blood flow in the heart, legs and other tissues by stimulating new blood vessel formation. The double-blind, placebo-controlled study is expected to enroll 100 patients and will assess walking distance on a treadmill and patient well being, as well as safety and tolerance. The product already is in Phase II for coronary artery disease.
¿Gum Tech International, of Phoenix, which originated as a functional chewing gum company, said its board approved a proposal to expand its business strategy to tar-get the drug delivery business. The company plans to change its name, and will consider acquiring or merging with existing delivery companies.
¿Micrologix Biotech Inc., of Vancouver, British Columbia, said its board adopted a shareholder rights plan. The plan is effective immediately and subject to regulatory approval and shareholder ratification at its Sept. 7 annual meeting.
¿Millennium Pharmaceuticals Inc., of Cambridge, Mass., opened an office in Tokyo to help facilitate business opportunities in Japan and Asia while providing a local presence for its existing partnerships. The move also is designed to increase awareness of the company's technologies among Japanese pharmaceutical companies.
¿Maxim Pharmaceuticals Inc., of San Diego, entered into an agreement with F. Hoffmann-La Roche Ltd., of Basel, Switzerland, and its U.S. subsidiary for development of Maxim's Maxamine in combination with Pegasys, Roche's pegylated interferon-alpha product. They are going to evaluate the combination in certain cancers and hepatitis C. The program will include two Phase Ill trials of the combination therapy for hepatitis C and one Phase III trial in advanced-stage renal cell carcinoma, as well as one in another cancer indication. Roche will perform the management, monitoring and data management of the trials at its own cost and Roche and Maxim will share equally the third-party costs of the trials. Each company will retain marketing responsibilities and revenues for its respective drugs, although under the collaboration agreement they will cooperate in the training of their respective sales forces.
¿Sequenom Inc., of San Diego, and the University of Texas Southwestern Medical Center at Dallas are collaborating to discover associations between single nucleotide polymorphisms and cardiovascular disease. UT Southwestern will contribute nearly 700,000 SNP candidates along with more than 3,500 DNA samples linked to cardiovascular disease. Sequenom will analyze the SNP candidates.